Table 4e. Characteristics of Antiviral Agents, Including Antibody Products
Last Updated: April 20, 2023
- This table contains drugs and products that have shown antiviral activity against SARS-CoV-2, including small-molecule antiviral drugs, CCP, and IFNs.
- RDV is the only antiviral drug that is approved by the FDA for the treatment of COVID-19.
- RTV-boosted nirmatrelvir, MOV, and CCP have received EUAs from the FDA for the treatment of COVID-19.
- For drug-drug interaction information, please refer to product labels, EUA fact sheets, and Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications.
- For the Panel’s recommendations on using the drugs listed in this table, refer to the individual drug sections; Therapeutic Management of Nonhospitalized Adults With COVID-19; Therapeutic Management of Hospitalized Adults With COVID-19; Therapeutic Management of Nonhospitalized Children With COVID-19; Antiviral Agents, Including Antibody Products; and Pregnancy, Lactation, and COVID-19 Therapeutics.
Table 4e. Characteristics of Antiviral Agents, Including Antibody Products | |
---|---|
References
- Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Paxlovid. 2023. Available at: https://www.fda.gov/media/155050/download.
- BC COVID Therapeutics Committee (CTC) COVID Therapy Review and Advisory Working Group (CTRAWG). Therapeutic brief: crushing nirmatrelvir/ritonavir (Paxlovid). 2022. Available at: http://www.bccdc.ca/Health-Professionals-Site/Documents/COVID-treatment/Crushing_Paxlovid.pdf.
- Remdesivir (Veklury) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214787Orig1s015lbl.pdf.
- Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Lagevrio (molnupiravir) capsules. 2023. Available at: https://www.fda.gov/media/155054/download.
- Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization (EUA) of COVID-19 convalescent plasma for treatment of coronavirus disease 2019 (COVID-19). 2021. Available at: https://www.fda.gov/media/141478/download.